Disposition of 38000 shares by Robert Blanks of Ardelyx at 5.955 subject to Rule 16b-3
| ARDX Stock | USD 5.36 0.12 2.19% |
Slightly above 61% of Ardelyx's investor base is looking to short. The analysis of the overall investor sentiment regarding Ardelyx suggests that many traders are alarmed. Ardelyx's investing sentiment can be driven by a variety of factors including economic data, Ardelyx's earnings reports, geopolitical events, and overall market trends.
Ardelyx |
Filed transaction by Ardelyx Officer: See Remarks. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Ardelyx Fundamental Analysis
We analyze Ardelyx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ardelyx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ardelyx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Ardelyx is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Ardelyx Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ardelyx stock to make a market-neutral strategy. Peer analysis of Ardelyx could also be used in its relative valuation, which is a method of valuing Ardelyx by comparing valuation metrics with similar companies.
Peers
Ardelyx Related Equities
| PDSB | PDS Biotechnology | 9.21 | ||||
| MCRB | Seres Therapeutics | 6.17 | ||||
| HEPA | Hepion Pharmaceuticals | 5.56 | ||||
| VSTM | Verastem | 3.15 | ||||
| INZY | Inozyme Pharma | 2.82 | ||||
| MREO | Mereo BioPharma | 2.09 | ||||
| ZURA | Zura Bio | 1.73 | ||||
| HOOK | Hookipa Pharma | 0.50 | ||||
| TERN | Terns Pharmaceuticals | 6.28 | ||||
| BLRX | BioLineRx | 15.40 |
Additional Tools for Ardelyx Stock Analysis
When running Ardelyx's price analysis, check to measure Ardelyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ardelyx is operating at the current time. Most of Ardelyx's value examination focuses on studying past and present price action to predict the probability of Ardelyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ardelyx's price. Additionally, you may evaluate how the addition of Ardelyx to your portfolios can decrease your overall portfolio volatility.